As of 2026-10-09, the Intrinsic Value of Eupraxia Pharmaceuticals Inc (EPRX.TO) is -3.42 CAD. This EPRX.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 11.01 CAD, the upside of Eupraxia Pharmaceuticals Inc is -131.06%.
Based on its market price of 11.01 CAD and our intrinsic valuation, Eupraxia Pharmaceuticals Inc (EPRX.TO) is overvalued by 131.06%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.42 - -3.42 | -3.42 | -131.06% |
| DDM - Stable | (3.61) - (7.44) | (5.53) | -150.2% |
| DDM - Multi | (0.05) - (0.07) | (0.06) | -100.5% |
| Market Cap (mil) | 715.87 |
| Beta | 1.25 |
| Outstanding shares (mil) | 65.02 |
| Enterprise Value (mil) | 657.37 |
| Market risk premium | 5.10% |
| Cost of Equity | 14.76% |
| Cost of Debt | 5.00% |
| WACC | 9.88% |